Bernstein Maintains Outperform on Regeneron Pharmaceuticals, Lowers Price Target to $921
Regeneron Pharmaceuticals, Inc. -0.15% Pre
Regeneron Pharmaceuticals, Inc. REGN | 749.41 749.41 | -0.15% 0.00% Pre |
Bernstein analyst William Pickering maintains Regeneron Pharmaceuticals (NASDAQ:
REGN) with a Outperform and lowers the price target from $925 to $921.
